Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I study of durvalumab and tremelimumab together with radiotherapy for the adjuvant treatment of intermediate-risk head and neck squamous cell carcinoma.
Authors
Siddharth Sheth
University of North Carolina, Chapel Hill, NC
Siddharth Sheth, Bhishamjit S. Chera, Benjamin Garrett Vincent, Colette J. Shen, Mark Christian Weissler, Jeffrey Blumberg, Samip Patel, Adam M. Zanation, Wendell Gray Yarbrough, Shetal Arvind Patel, Juneko E. Grilley-Olson, Trevor Hackman, Jared Weiss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT03529422
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr TPS73)
DOI
10.1200/JCO.2019.37.8_suppl.TPS73
Abstract #
TPS73
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer.
First Author: Steven H. Lin
Poster
2020 ASCO Virtual Scientific Program
A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).
First Author: Markus Hecht
Poster
2023 ASCO Annual Meeting
Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.
First Author: Houda Bahig
Poster
2023 ASCO Annual Meeting
TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).
First Author: Hossein Borghaei